Herpes Zoster

@article{Schmader2018HerpesZ,
  title={Herpes Zoster},
  author={Kenneth E. Schmader},
  journal={Annals of Internal Medicine},
  year={2018},
  volume={169},
  pages={ITC17-ITC32}
}
  • K. Schmader
  • Published 7 August 2018
  • Medicine
  • Annals of Internal Medicine
Herpes zoster, a painful rash that is commonly known as shingles, occurs in approximately 1 million people in the United States annually (1). Anyone who has had primary infection with varicella zoster virus, which usually manifests as varicella (chickenpox), can develop herpes zoster. About 95% of the adult U.S. population is latently infected with varicella zoster virus and thus can have herpes zoster. Approximately one third of persons will have an episode of herpes zoster, and frequency… Expand
4 Citations

Paper Mentions

Intravenous Administration of Vitamin C in the Treatment of Herpes Zoster-Associated Pain: Two Case Reports and Literature Review
TLDR
The use of vitamin C appears to be an emerging treatment alternative for attenuating HZ and PHN pain and the addition of concomitant use of intravenously administered vitamin C into therapeutic strategies in the treatment of HZ-associated pain is recommended, especially for therapy-resistant cases. Expand
Shingles: Not Just a Rash
TLDR
Herpes zoster infection occurs in 1 of 3 people in their lifetime and can lead to a painful, blistery rash, which can last for months to years. Expand
Supraorbital Nerve Radiofrequency for Severe Neuralgia Caused by Herpes Zoster Ophthalmicus
TLDR
CT-guided supraorbital nerve radiofrequency thermocoagulation for the treatment of OHN can effectively relieve pain and reduce the dose of analgesics, without any serious complication. Expand
Vaccination (Prophylaxis) in the Elderly
TLDR
This article will review the main diseases where vaccination has the greatest potential effect (namely, influenza, pneumococcal disease, and herpes zoster), as well as current and future strategies to improve vaccine efficacy. Expand

References

SHOWING 1-10 OF 11 REFERENCES
Safety of Herpes Zoster Vaccine in the Shingles Prevention Study
TLDR
Herpes zoster vaccine is well tolerated in older, immunocompetent adults and long-term follow-up showed that rates of hospitalization or death did not differ between vaccine and placebo recipients. Expand
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
TLDR
HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. Expand
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.
  • K. Schmader, M. Levin, +12 authors J. Parrino
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
In subjects aged 50-59 years, the ZV significantly reduced the incidence of HZ and was well tolerated, with the difference primarily due to higher rates of injection-site AEs and headache. Expand
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
TLDR
The HZ/su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or older and was similar to that in the other two age groups. Expand
Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.
  • K. Schmader, M. Oxman, +18 authors P. Annunziato
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
There is evidence of the persistence of vaccine efficacy through year 5 after vaccination but, vaccine efficacy is uncertain beyond that point. Expand
The postmarketing safety profile of varicella vaccine.
The postmarketing safety profile of varicella vaccine was evaluated by analyzing selected adverse experience reports temporally associated with the administration of the vaccine. There were 7963Expand
Long-term persistence of zoster vaccine efficacy.
  • V. Morrison, G. Johnson, +21 authors M. Oxman
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2015
TLDR
Estimates of vaccine efficacy decreased over time in the LTPS population compared with modeled control estimates, and declined for all 3 outcome measures from 7 through 11 years postvaccination. Expand
Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018*
TLDR
The adult immunization schedule is to assist health care providers in implementing the current ACIP recommendations for vaccinating adults and contains information on general principles on immunization for adults; considerations for special populations, such as pregnant women; reference resources pertinent to adult Immunization; instructions for reporting adverse events and suspected cases of reportable vaccine-preventable diseases. Expand
Safety and Immunogenicity Profile of the Concomitant Administration of ZOSTAVAX and Inactivated Influenza Vaccine in Adults Aged 50 and Older
TLDR
The safety and immunogenicity of ZOSTAVAX administered concomitantly with inactivated influenza vaccine or sequentially in adults aged 50 and older is evaluated. Expand
...
1
2
...